» Articles » PMID: 39364131

Cross Interaction Between Bacterial and Fungal Microbiota and Their Relevance to Human Health and Disease: Mechanistic Pathways and Prospective Therapy

Overview
Specialty Biology
Date 2024 Oct 4
PMID 39364131
Authors
Affiliations
Soon will be listed here.
Abstract

Diverse bacterial and fungal microbiota communities inhabit the human body, and their presence is essential for maintaining host homeostasis. The oral cavity, lung, gut, and vagina are just a few of the bodily cavities where these microorganisms communicate with one another, either directly or indirectly. The effects of this interaction can be either useful or detrimental to the host. When the healthy microbial diversity is disturbed, for instance, as a result of prolonged treatment with broad spectrum antibiotics, this allows the growth of specific microbes at the expense of others and alters their pathogenicity, causing a switch of commensal germs into pathogenic germs, which could promote tissue invasion and damage, as occurs in immunocompromised patients. Consequently, antimicrobials that specifically target pathogens may help in minimizing secondary issues that result from the disruption of useful bacterial/fungal interactions (BFIs). The interface between and with bacteria at various body sites is emphasized in the majority of the medically important BFIs that have been reported thus far. This interface either supports or inhibits growth, or it enhances or blocks the generation of virulence factors. The aim of this review is to draw attention to the link between the bacterial and fungal microbiota and how they contribute to both normal homeostasis and disease development. Additionally, recent research that has studied microbiota as novel antimicrobials is summarized.

References
1.
Raffa N, Won T, Sukowaty A, Candor K, Cui C, Halder S . Dual-purpose isocyanides produced by contribute to cellular copper sufficiency and exhibit antimicrobial activity. Proc Natl Acad Sci U S A. 2021; 118(8). PMC: 7923669. DOI: 10.1073/pnas.2015224118. View

2.
Morales D, Grahl N, Okegbe C, Dietrich L, Jacobs N, Hogan D . Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. mBio. 2013; 4(1):e00526-12. PMC: 3560528. DOI: 10.1128/mBio.00526-12. View

3.
Rogiers O, Holtappels M, Siala W, Lamkanfi M, Van Bambeke F, Lagrou K . Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies. J Antimicrob Chemother. 2018; 73(10):2806-2814. DOI: 10.1093/jac/dky246. View

4.
Zhang Z, Lv J, Pan L, Zhang Y . Roles and applications of probiotic Lactobacillus strains. Appl Microbiol Biotechnol. 2018; 102(19):8135-8143. DOI: 10.1007/s00253-018-9217-9. View

5.
Zandbergen L, Halverson T, Brons J, Wolfe A, de Vos M . The Good and the Bad: Ecological Interaction Measurements Between the Urinary Microbiota and Uropathogens. Front Microbiol. 2021; 12:659450. PMC: 8141646. DOI: 10.3389/fmicb.2021.659450. View